• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

PTNS therapy for OAB found durable at 3 years

Article

The effect of percutaneous tibial nerve stimulation in patients with overactive bladder appears to be durable at up to 3 years, a recently published study demonstrates.

The effect of percutaneous tibial nerve stimulation (PTNS) in patients with overactive bladder appears to be durable at up to 3 years, a recently published study demonstrates.

Patients in the multicenter STEP Study who initially responded to 12 weekly PTNS treatments using the Urgent PC Neuromodulation System (Uroplasty, Inc., Minneapolis) were followed for 36 months and received PTNS therapy throughout. Patients received an average of 1.1 treatments per month and sustained statistically significant improvements in voiding frequency, urinary urge incontinence episodes, nighttime voids, urgency episodes, and voids with moderate to severe urgency, voiding volume and quality of life measures compared to before they began treatment.

There were no serious adverse events reported throughout the study, results of which were reported in the Journal of Urology (2013; 189:2194-2201).

“We are pleased that this long-term study demonstrates the durability of the effect of PTNS over 3 years,” said lead investigator Kenneth M. Peters, MD, of Beaumont Hospital in Royal Oak, MI. “This study demonstrates that with ongoing therapy, OAB patients can continue to sustain improvement in their OAB symptoms. With continuing therapy, patients’ symptoms can be controlled at a level that positively impacts their quality of life.”

Dr. Peters has disclosed a financial interest and/or other relationship with Uroplasty, Medtronic, EMKinetics, and TARIS.

Related Content

Newer OAB agent viable alternative to antimuscarinics

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
A panel of 4 experts on prostate cancer
A panel of experts on prostate cancer
A panel of 4 experts on prostate cancer
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
A panel of 4 experts on prostate cancer
A panel of 5 experts on bladder cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.